Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)

• Published in: BMJ open 2022-12, Vol.12 (12), p.e066252
• Main Authors: Maier, Rebecca H, Plummer, Chris, Kasim, Adetayo S, Akhter, Nasima, Ogundimu, Emmanuel, Maddox, Jamie, Graham, Janine, Stewart, Michael, Wardley, Andrew, Haney, Sophie, Vahabi, Sharareh, Oxenham, Helen, Humphreys, Alison, Cresti, Nicola, Verrill, Mark, Graham, Richard, Chang, Lisa, Hancock, Helen C, Austin, David
• Format: Article
• Language: English
• Subjects: Adult; Anthracyclines - adverse effects; Antibiotics, Antineoplastic - adverse effects; Apoptosis; Asymptomatic; Breast cancer; Breast Neoplasms - pathology; Cancer therapies; Cardiotoxicity; Cardiotoxicity - etiology; Cardiotoxicity - prevention & control; Cardiovascular Medicine; Chemotherapy; Cost control; Enalapril - therapeutic use; Female; Heart failure; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Medical prognosis; Multicenter Studies as Topic; Patients; Prospective Studies; Randomized Controlled Trials as Topic; Systematic review
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-066252

Anthracyclines are included in chemotherapy regimens to treat several different types of cancer and are extremely effective. However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversible damage to cardiac cells and ultimately impaired cardiac function and heart failure, which may only be evident years after exposure. The PROACT trial will establish the effectiveness of the ACE inhibitor enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin's lymphoma (NHL) receiving anthracycline-based chemotherapy. PROACT is a prospective, randomised, open-label, blinded end-point, superiority trial which will recruit adult patients being treated for breast cancer and NHL at NHS hospitals throughout England. The trial aims to recruit 106 participants, who will be randomised to standard care (high-dose anthracycline-based chemotherapy) plus enalapril (intervention) or standard care alone (control). Patients randomised to the intervention arm will receive enalapril (starting at 2.5 mg two times per day and titrating up to a maximum dose of 10 mg two times per day), commencing treatment at least 2 days prior to starting chemotherapy and finishing 3 weeks after their last anthracycline dose. The primary outcome is the presence or absence of cardiac troponin T release at any time during anthracycline treatment, and 1 month after the last dose of anthracycline. Secondary outcomes will focus on cardiac function measured using echocardiogram assessment, adherence to enalapril and side effects. A favourable opinion was given following research ethics committee review by West Midlands-Edgbaston REC, Ref: 17/WM/0248. Trial findings will be disseminated through engagement with patients, the oncology and cardiology communities, NHS management and commissioning groups and through peer-reviewed publication. NCT03265574.